Lipoprotein-Associated Phospholipase A₂ Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus

Table 1

Characteristics of subjects.

Total of subjects enrolled	44
Male	19 (43.2%)
Age (years)	79.6±5.6
BMI (kg/m^2)	27.6±4.7
Systolic BP (mmHg)	133±18
Diastolic BP (mmHg)	75±10
Total patients after TAVI	35
(a) apical route	8
(b) femoral route	27
Total patients after BA	9
Total patients with DM	21 (47.7%)
(a) on insulin therapy	9
(b) on peroral antidiabetics	3
(c) DM controlled by diet	9
Total cholesterol (mmol/L)	4.16±1.17
HDL-C (mmol/L)	1.25±0.44
LDL-C (mmol/L)	2.48±0.96
Triglycerides (mmol/L)	1.36±0.66
CRP (mg/L)	20.8 [0.5–75.1]
Lp-PLA2 (ng/mL)	1320±342
(a) Lp-PLA2 on TAVI group	1296±358
(b) Lp-PLA2 on BA group	1413±268

Measurements are expressed as mean ± SD or as total number, with the exception of CRP (median [range]). BP: blood pressure, TAVI: transcatheter aortic valve implantation, DM: diabetes mellitus, HDL-C: high-density lipoprotein concentration, LDL-C: low-density lipoprotein concentration, CRP: C-reactive protein, Lp-PLA₂: lipoprotein-associated phospholipase A₂, and BA: balloon angioplasty.